Provided by Tiger Fintech (Singapore) Pte. Ltd.

Capricor Therapeutics

14.23
+1.057.97%
Post-market: 14.590.3600+2.53%19:59 EDT
Volume:2.51M
Turnover:35.06M
Market Cap:650.42M
PE:-10.02
High:14.35
Open:13.26
Low:12.80
Close:13.18
Loading ...

Capricor Therapeutics' Biologics License Application for Deramiocel Accepted by FDA

MT Newswires Live
·
10 Mar

Capricor Therapeutics Inc - FDA Grants Priority Review for Deramiocel With Pdufa Date August 31, 2025

THOMSON REUTERS
·
10 Mar

FDA Accepts Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy Treatment

THOMSON REUTERS
·
10 Mar

FDA Accepts Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy Treatment

PR Newswire
·
10 Mar

Capricor Therapeutics Inc expected to post a loss of 26 cents a share - Earnings Preview

Reuters
·
07 Mar

Capricor Therapeutics, Inc. (CAPR): A Bull Case Theory

Insider Monkey
·
07 Mar

Capricor Therapeutics options imply 7.5% move in share price post-earnings

TIPRANKS
·
06 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
05 Mar

BUZZ-U.S. STOCKS ON THE MOVE-Okta, Natgas companies, UnitedHealth

Reuters
·
05 Mar

Capricor Therapeutics Price Target Maintained With a $77.00/Share by HC Wainwright & Co.

Dow Jones
·
05 Mar

Capricor Therapeutics Cell Therapy Goes Under Priority FDA Review For Duchenne Associated-Heart Condition

Benzinga
·
05 Mar

Capricor Therapeutics: Promising Developments and Strategic Positioning Drive Buy Rating

TIPRANKS
·
04 Mar

Capricor Therapeutics Shares Rise on FDA Priority Review

Dow Jones
·
04 Mar

Capricor Therapeutics Shares up 10.1% After FDA Grants Priority Review to Co's Therapy for a Muscle-Wasting Related Heart Condition

THOMSON REUTERS
·
04 Mar

BUZZ-U.S. STOCKS ON THE MOVE-Wellgistics, Capricor, Wave Life Sciences

Reuters
·
04 Mar

BUZZ-Capricor rises on FDA's priority review for Duchenne muscular dystrophy-related cell therapy

Reuters
·
04 Mar

Capricor Therapeutics Shares Gain 10.6% Premarket After FDA Grants Priority Review to Co's Therapy for a Muscle-Wasting Related Heart Condition

THOMSON REUTERS
·
04 Mar

Capricor Therapeutics Receives FDA's Acceptance for Review of BLA for Duchenne Muscular Dystrophy Treatment

MT Newswires Live
·
04 Mar

Analysts Conflicted on These Healthcare Names: Pliant Therapeutics (PLRX) and Capricor Therapeutics (CAPR)

TIPRANKS
·
04 Mar

Capricor Therapeutics' Cell Therapy for Muscular Dystrophy Patients to Get FDA Priority Review

Dow Jones
·
04 Mar